pfizer glp-1 drug Pfizer's Push into GLP‑1 Drugs Signals a New Era in Obesity Treatment — and a Pfizer scraps daily weight loss

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways

As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)

Satiety regulation (reduces appetite, aiding in weight loss)

INTRODUCTION:While ubiquity of glucagon-like peptide receptor agonists (GLP1-RAs) is rising, guidance from the gastroenterology societies and...

In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need

Data are presented as median (interquartile range)